Not Signed In -
Arsenic |
|
|
33 germanium ← arsenic → selenium P ↑ As ↓ Sb periodic table General Name, Symbol, Number arsenic, As, 33 Chemical series metalloids Group, Period, Block 15, 4, p Appearance metallic gray Atomic mass 74.92160(2) g/mol Electron configuration [Ar] 3d10 4s2 4p3 Electrons per shell 2, 8, 18, 5 Physical properties Phase solid Density (near r.t.) 5.727 g·cm−3 Liquid density at m.p. 5.22 g·cm−3 Melting point 1090 K (817 °C, 1503& ...
Wikipedia - [full article]
Arsenic Clinical Trials
- Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
ClinicalTrials.gov Identifier: NCT00045565 - Active, not recruiting
adult glioblastoma
- Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
ClinicalTrials.gov Identifier: NCT00006220 - Active, not recruiting
Leukemia; Lymphoma
- Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or With Chronic Myelogenous Leukemia
ClinicalTrials.gov Identifier: NCT00003885 - Active, not recruiting
Leukemia; Lymphoma; Multiple Myeloma
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
ClinicalTrials.gov Identifier: NCT00005595 - Active, not recruiting
recurrent adult Hodgkin's disease
- Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00104806 - Active, not recruiting
Chronic Myelomonocytic Leukemia; myelodysplastic and myeloproliferative disease; Myelodysplastic Syndromes
- Arsenic Trioxide in Treating Patients With Recurrent Bladder or Urinary Tract Cancer
ClinicalTrials.gov Identifier: NCT00009867 - Active, not recruiting
recurrent urethral cancer; transitional cell carcinoma of the bladder; recurrent bladder cancer; ...
- Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
ClinicalTrials.gov Identifier: NCT00185861 - Active, not recruiting
Brain Tumor
- Azacitidine and Arsenic Trioxide in Treating Patients with Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00118196 - Active, not recruiting
de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes
- Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00020969 - Active, not recruiting
atypical chronic myeloid leukemia; Chronic Myelomonocytic Leukemia; myelodysplastic and myeloproliferative disease; Myelodysplastic Syndromes
- Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00075413 - Active, not recruiting
stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent breast cancer; stage IIIA breast cancer
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
ClinicalTrials.gov Identifier: NCT00053248 - Active, not recruiting
chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
- Arsenic Trioxide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017433 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00075426 - Active, not recruiting
stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; ...
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017069 - Active, not recruiting
refractory plasma cell neoplasm; stage II multiple myeloma; stage III multiple myeloma
- Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
ClinicalTrials.gov Identifier: NCT00095771 - Recruiting
untreated childhood brain stem glioma; high-grade childhood cerebral astrocytoma
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124605 - Active, not recruiting
unspecified adult solid tumor, protocol specific; refractory plasma cell neoplasm; stage III multiple myeloma; stage II multiple myeloma
- Iodine I 131 Metaiodobenzylguanidine and Arsenic Trioxide in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
ClinicalTrials.gov Identifier: NCT00107289 - Recruiting
metastatic pheochromocytoma; recurrent pheochromocytoma; regional pheochromocytoma; recurrent neuroblastoma
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00227682 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00234000 - Recruiting
Leukemia
- Effects of Arsenic on Keratinocytes in a Skin Equivalent Model
ClinicalTrials.gov Identifier: NCT00166946 - Recruiting
Bowen Disease
- Tretinoin, Cytarabine, and Daunorubicin With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
ClinicalTrials.gov Identifier: NCT00003934 - Active, not recruiting
untreated adult acute myeloid leukemia; untreated childhood acute myeloid leukemia and other myeloid malignancies; ...
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00193544 - Active, not recruiting
Multiple Myeloma
- All-Trans Retinoic Acid, and Arsenic +/- Gemtuzumab and Theophylline
ClinicalTrials.gov Identifier: NCT00413166 - Recruiting
Acute Promyelocytic Leukemia
- Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
ClinicalTrials.gov Identifier: NCT00008697 - Active, not recruiting
recurrent childhood acute myeloid leukemia; recurrent adult acute myeloid leukemia; adult acute promyelocytic leukemia (M3); ...
- Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
ClinicalTrials.gov Identifier: NCT00128596 - Recruiting
adult primary hepatocellular carcinoma; advanced adult primary liver cancer; recurrent adult primary liver cancer
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00085345 - Recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
ClinicalTrials.gov Identifier: NCT00258245 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
ClinicalTrials.gov Identifier: NCT00275067 - Recruiting
Brain and Central Nervous System Tumors
- Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
ClinicalTrials.gov Identifier: NCT00528450 - Recruiting
Leukemia
- Pilot Trial of Arsenic + Ara-C in Patients With Myelofibrosis
ClinicalTrials.gov Identifier: NCT00572065 - Recruiting
Myelofibrosis
- A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
ClinicalTrials.gov Identifier: NCT00582400 - Recruiting
Carcinoma, Hepatocellular
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112879 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
ClinicalTrials.gov Identifier: NCT00093483 - Recruiting
adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia
- Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00274781 - Recruiting
Leukemia; Myelodysplastic Syndromes
- Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
ClinicalTrials.gov Identifier: NCT00571116 - Recruiting
Metastatic Melanoma
- Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
ClinicalTrials.gov Identifier: NCT00449137 - Recruiting
Colorectal Cancer
- Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.gov Identifier: NCT00193518 - Active, not recruiting
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia
ClinicalTrials.gov Identifier: NCT00184054 - Recruiting
Acute Myelogenous Leukemia
- Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
ClinicalTrials.gov Identifier: NCT00517712 - Recruiting
Acute Promyelocytic Leukemia
- Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00003395 - Completed
Leukemia; Lymphoma; Multiple Myeloma
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Chronic Idiopathic Myelofibrosis or Myelodysplastic or Myeloproliferative Disorders
ClinicalTrials.gov Identifier: NCT00274820 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
- Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006021 - Completed
refractory plasma cell neoplasm
- Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia
ClinicalTrials.gov Identifier: NCT00513305 - Recruiting
Acute Myeloid Leukemia
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
ClinicalTrials.gov Identifier: NCT00504764 - Not yet recruiting
Acute Promyelocytic Leukemia
- Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
ClinicalTrials.gov Identifier: NCT00024258 - Suspended
childhood cancer
- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
ClinicalTrials.gov Identifier: NCT00196768 - Recruiting
Relapsed Acute Promyelocytic Leukemia; Refractory Acute Promyelocytic Leukemia
- Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
ClinicalTrials.gov Identifier: NCT00016159 - Active, not recruiting
adult acute myeloid leukemia in remission; childhood acute myeloid leukemia in remission; adult acute promyelocytic leukemia (M3); ...
- Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
ClinicalTrials.gov Identifier: NCT00004149 - Completed
stage IV prostate cancer; recurrent prostate cancer
- Arsenic Trioxide to Treat Children with Leukemia or Lymphoma
ClinicalTrials.gov Identifier: NCT00004548 - Completed
Acute Promyelocytic Leukemia; Leukemia; Lymphoma
- Arsenic Trioxide in Treating Men With Germ Cell Cancer
ClinicalTrials.gov Identifier: NCT00036842 - Completed
recurrent testicular cancer; extragonadal germ cell tumor
- Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
ClinicalTrials.gov Identifier: NCT00061958 - Completed
Adenocarcinoma of the Esophagus; stage III esophageal cancer; stage IV esophageal cancer
- Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00006090 - Completed
refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
- Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00093366 - Completed
de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; ...
- Arsenic Trioxide in Combination With Cytarabine in Patients With High-Risk MDS and Poor-Prognosis AML
ClinicalTrials.gov Identifier: NCT00195104 - Completed
Myelodysplastic Syndrome
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
ClinicalTrials.gov Identifier: NCT00005786 - Completed
adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma; Prolymphocytic Leukemia; ...
- Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
ClinicalTrials.gov Identifier: NCT00005069 - Completed
Stage IV Renal Cell Cancer; childhood kidney/urinary cancer; recurrent renal cell cancer
- Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
ClinicalTrials.gov Identifier: NCT00003630 - Completed
unspecified childhood solid tumor, protocol specific; unspecified adult solid tumor, protocol specific
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
ClinicalTrials.gov Identifier: NCT00006008 - Completed
L3 adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; recurrent adult acute lymphoblastic leukemia; ...
- Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
ClinicalTrials.gov Identifier: NCT00005999 - Completed
recurrent cervical cancer; cervical squamous cell carcinoma; cervical adenocarcinoma; stage IVB cervical cancer
- Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
ClinicalTrials.gov Identifier: NCT00053222 - Completed
recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; ...
- A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
ClinicalTrials.gov Identifier: NCT00250042 - Completed
Leukemia, Other; Cancer
- Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
ClinicalTrials.gov Identifier: NCT00006091 - Completed
Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; refractory chronic myelogenous leukemia
- Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
ClinicalTrials.gov Identifier: NCT00005795 - Completed
untreated adult acute myeloid leukemia; adult acute differentiated monocytic leukemia (M5b); ...
- Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
ClinicalTrials.gov Identifier: NCT00006092 - Completed
recurrent adult acute lymphoblastic leukemia; relapsing chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; ...
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
ClinicalTrials.gov Identifier: NCT00005618 - Completed
accelerated phase chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; refractory chronic myelogenous leukemia; ...
- Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
ClinicalTrials.gov Identifier: NCT00020111 - Completed
Leukemia; Lymphoma
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00005040 - Completed
recurrent adult diffuse small cleaved cell lymphoma; recurrent adult lymphoblastic lymphoma; recurrent grade III follicular large cell lymphoma; ...
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
ClinicalTrials.gov Identifier: NCT00081133 - Completed
accelerated phase chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; recurrent adult acute lymphoblastic leukemia; ...
- Bladder Cancer Case Control Study of Arsenic in Water
ClinicalTrials.gov Identifier: NCT00011518 - Completed
Bladder Cancer
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00201695 - Suspended
Multiple Myeloma
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00504101 - Suspended
Multiple Myeloma and Plasma Cell Neoplasm
- Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov Identifier: NCT00225992 - Terminated
Myelodysplastic Syndrome (MDS)
Resources
- Agency for Toxic Substances and Disease Registry
- Arsenic (Agency for Toxic Substances and Disease Registry)
email this page
print this page
bookmark this page
feedback on this page
